中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

52 records (took 0.049 seconds)

    Prostate cancer specific internalizing human antibodies
    11.
    发明授权
    Prostate cancer specific internalizing human antibodies 有权
    前列腺癌特异性内化人抗体

    公开(公告)号：US07335744B2

    公开(公告)日：2008-02-26

    申请号：US11021438

    申请日：2004-12-21

    Applicant: Bin Liu ,  James D. Marks

    Inventor： Bin Liu ,  James D. Marks

    IPC: C12P21/08

    CPC classification number: C07K16/3069 ,  A61K2039/505 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/77

    Abstract: This invention provides novel prostate cancer specific internalizing human antibodies. The antibodies are useful by themselves to prevent growth and/or proliferation of prostate cancer cells. The antibodies can also be formulated as chimeric molecules to direct an effector (e.g. a cytotoxin, an imaging reagent, a drug, etc.) to a prostate tumor site.

    Abstract translation: 本发明提供了新型前列腺癌特异性内化人抗体。 抗体本身可用于预防前列腺癌细胞的生长和/或增殖。 抗体还可以配制成嵌合分子以将效应物（例如细胞毒素，成像试剂，药物等）引导至前列腺肿瘤部位。

    Methods of selecting internalizing antibodies
    12.
    发明授权
    Methods of selecting internalizing antibodies 失效
    选择内化抗体的方法

    公开(公告)号：US06794128B2

    公开(公告)日：2004-09-21

    申请号：US09249529

    申请日：1999-02-12

    Applicant: James D. Marks ,  Marie Alix Poul ,  Baltazar Becerril

    Inventor： James D. Marks ,  Marie Alix Poul ,  Baltazar Becerril

    IPC: C12Q100

    CPC classification number: C12N15/1037 ,  A61K38/00 ,  A61K47/6843 ,  C07K14/005 ,  C07K16/2863 ,  C07K16/2881 ,  C07K16/32 ,  C07K2317/21 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/77 ,  C07K2319/02 ,  C12N15/86 ,  C12N2795/10022

    Abstract: This invention provides methods of selecting antibodies that are internalized into target cells. The methods generally involve contacting target cells with one or more members of an antibody phage display library. The members of the phage display library are also contacted with cells of a subtractive cell line. The target cells are then washed to remove the subtractive cell line cells and members of the phage display library that are non-specifically bound or weakly bound to the target cells. The target cells are cultured under conditions where members of the phage display library can be internalized if bound to an internalizing marker and internalized members of the phage display library are then identified.

    Abstract translation: 本发明提供了选择内化于靶细胞中的抗体的方法。 所述方法通常涉及使靶细胞与抗体噬菌体展示文库的一个或多个成员接触。 噬菌体展示文库的成员也与减数细胞系的细胞接触。 然后洗涤靶细胞以除去非特异性结合或弱结合到靶细胞的消减细胞系细胞和噬菌体展示文库的成员。 靶细胞在噬菌体展示文库的成员可以内化的条件下培养，如果结合到内化标记物，然后鉴定噬菌体展示文库的内化成员。

    Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
    19.
    发明授权
    Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins 有权
    中和肉毒杆菌神经毒素的治疗性单克隆抗体

    公开(公告)号：US08299218B2

    公开(公告)日：2012-10-30

    申请号：US12468526

    申请日：2009-05-19

    Applicant: James D. Marks ,  Ali Razai

    Inventor： James D. Marks ,  Ali Razai

    IPC: C07K16/00 ,  C12P21/08 ,  G01N33/53

    CPC classification number: C07K16/1282 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/622

    Abstract: This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.

    Abstract translation: 本发明提供了特异性结合并中和A型（BoNT / A）肉毒杆菌神经毒素和由这些抗体结合的表位的抗体。 特异性结合本文提供的中和表位的抗体及其衍生物和/或其他抗体可用于中和肉毒杆菌神经毒素，因此也可用于治疗肉毒中毒。

Patent Agency Ranking